EBM Eastwood Bio-Medical Canada Inc.
Eastwood Bio-Medical Canada Inc. markets, develops research, and distributes natural health products under the Eleotin brand in Canada, the United States, and Asia. The company distributes Eleotin, which provides natural remedies for metabolic disorders, such as blood glucose disorders, hypertension, and obesity. It also offers Eleotin A 700 for the treatment for spleen deficiency, lack of appetite, and fatigue; Eleotin AL88 for laxative; Eleotin Cal20 for bone and teeth maintenance; Eleotin V3D for bones, teeth, and health; Eleotin G2000 for cardiovascular health; Eleotin H55 for sedative and tension relief; and Eleotin Zn330 for tissue formation and metabolism. In addition, the company provides Eleotin Bentley to promote healthy glucose levels; and Eleotin LBM for hypertension relief. It has a joint research agreement with BioNexus Inc. to build a platform that applies artificial intelligence to herbal ingredient prescription data in order to identify natural drug and functional food product candidates. The company was incorporated in 2010 and is based in Richmond, Canada. Eastwood Bio-Medical Canada Inc. operates as a subsidiary of Eastwood Bio-Medical Research Inc.…
Industry Peers
BiotechnologyKey Statistics
About Eastwood Bio-Medical Canada (CVE: EBM)
›
Eastwood Bio-Medical Canada (CVE: EBM) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 1.630 CAD on 19 November 2026, up 171.7% over 52 weeks. Its 52-week range is 0.4900 CAD to 2.060 CAD: the price is 20.9% below the high and 232.7% above the low.
Its market capitalisation is 112.28M CAD.
Eastwood Bio-Medical Canada reports return on equity of 20.4%, an operating margin of -22.0% and revenue up 19.4% year over year.
Its debt exceeds its cash by 60.12K CAD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. The next earnings report is expected on 1 March 2027.